Glaucoma has long been treated as a plumbing problem — too much pressure inside the eye. But a growing body of research reframes it as a slow neurodegenerative disease of the optic nerve, where intraocular pressure is one important driver among several. In this episode, Dr. Saikumar Gandapodi joins us to unpack what that shift means for patients.

We explore why some people keep losing vision even when their pressure looks controlled, and what the evidence actually shows about ocular blood flow, mitochondrial stress, and the survival of retinal ganglion cells. Dr. Gandapodi explains Netra Restoration Therapy as an integrative, adjunct approach built around neuroprotection and whole-person care.

Throughout, the conversation stays grounded: what's established, what's still emerging, and where lowering pressure remains the foundation of care. This is a research-driven look at where glaucoma treatment may be heading.

Chronic diseases of the retina and optic nerve — glaucoma, certain macular and vascular retinopathies, optic neuropathies — often progress slowly and quietly, even when pressure or blood sugar looks controlled on paper. Why does damage sometimes continue, and what determines whether these delicate neural tissues hold up over time? In this episode, Dr. Saikumar Gandapodi joins the show to explore the concept of tissue resilience: the biology that lets retinal ganglion cells and the optic nerve withstand stress.

We unpack the mechanisms that genuinely matter for these tissues — ocular blood flow and vascular dysregulation, mitochondrial energy demand, oxidative stress, neurotrophin biology, and low-grade inflammation — and separate what's well established from what's still emerging. Dr. Gandapodi explains Netra Restoration Therapy as a multi-target, adjunctive framework meant to complement, never replace, standard ophthalmic care.

Throughout, the conversation stays evidence-honest: lab findings are distinguished from animal work and from human trials, herbal and traditional-medicine concepts are translated through modern network pharmacology, and no cures are promised. This is a thoughtful look at where conventional care is strong, where it has limits, and where complementary strategies may add value.

Chronic diseases of the retina and optic nerve — glaucoma, certain macular and vascular retinopathies, optic neuropathies — often progress slowly and quietly, even when pressure or blood sugar looks controlled on paper. Why does damage sometimes continue, and what determines whether these delicate neural tissues hold up over time? In this episode, Dr. Saikumar Gandapodi joins the show to explore the concept of tissue resilience: the biology that lets retinal ganglion cells and the optic nerve withstand stress.

We unpack the mechanisms that genuinely matter for these tissues — ocular blood flow and vascular dysregulation, mitochondrial energy demand, oxidative stress, neurotrophin biology, and low-grade inflammation — and separate what's well established from what's still emerging. Dr. Gandapodi explains Netra Restoration Therapy as a multi-target, adjunctive framework meant to complement, never replace, standard ophthalmic care.

Throughout, the conversation stays evidence-honest: lab findings are distinguished from animal work and from human trials, herbal and traditional-medicine concepts are translated through modern network pharmacology, and no cures are promised. This is a thoughtful look at where conventional care is strong, where it has limits, and where complementary strategies may add value.

In this episode, we sit down with Dr. Saikumar Gandapodi, Board-Certified Doctor of Oriental Medicine, Ayurvedic practitioner, and Founder and Director of Netra Eye Institute, to explore the tradition of Ayurvedic ophthalmology. We trace its classical roots in texts like the Sushruta Samhita, and then hold those ideas up against the standards of modern evidence.

Dr. Gandapodi explains how ancient concepts such as the doshas and Rakta Dhatu can serve as interpretive frameworks rather than literal biology, and how a handful of Ayurvedic botanicals are now being studied for oxidative stress and ocular surface health. He is candid about the limits of the current evidence, distinguishing laboratory findings from animal work from real human clinical trials.

We also discuss Netra Restoration Therapy, an integrative approach he frames strictly as a complement to standard ophthalmic care, and what an educated patient should take away when weighing tradition against trials.

Photobiomodulation, or PBM, uses low-level red and near-infrared light to influence cellular energy production. In ophthalmology, it's being studied most seriously for retinal conditions like dry age-related macular degeneration, where mitochondrial stress in the retina and RPE plays a central role. In this episode, Dr. Saikumar Gandapodi walks through the biology — how light interacts with cytochrome c oxidase, why the retina is uniquely metabolically demanding, and what recent human trials do and don't tell us.

We separate the established from the emerging at every turn. Dr. Gandapodi is candid about the limits: PBM is not a cure, dosing is still being worked out, and much of the mechanistic story comes from lab and animal models. He also explains how PBM fits into an integrative, whole-person framework at Netra Eye Institute — always as an adjunct to standard ophthalmic care, never a replacement.

This is a research-driven conversation for anyone curious about where light-based therapy is genuinely heading in eye medicine, and how to think critically about early but promising science.

Where systems biology, root-cause thinking, and standard eye care meet.

What does it actually mean to practice integrative ophthalmology, and how is it different from the eye care most patients already know? In this episode, Dr. Saikumar Gandapodi, Board-Certified Doctor of Oriental Medicine, Ayurvedic practitioner, and Founder of Netra Eye Institute, sits down to define an emerging clinical discipline that treats the eye as part of the whole body rather than an isolated organ.

We explore where conventional ophthalmology excels, where chronic eye disease leaves gaps, and how concepts like ocular blood flow, oxidative stress, inflammation, and the gut-eye axis are being studied as contributors to disease. Dr. Gandapodi explains Netra Restoration Therapy as a multi-target, adjunctive approach, and he is candid throughout about what is established versus what remains early and hypothesis-generating.

This is a research-driven conversation for an educated audience curious about the future of eye health, told without hype and without dismissing the surgery and pharmaceuticals that save sight every day.

Age-related macular degeneration is usually described as a problem of aging and drusen. But a growing body of research points to something deeper: a slow failure of energy metabolism in the retina and the cells that support it. In this episode, Dr. Saikumar Gandapodi, Founder and Director of Netra Eye Institute, reframes AMD as a disease of metabolic exhaustion in the retinal pigment epithelium and photoreceptors.

We explore why the macula is metabolically the most demanding tissue in the body, how mitochondrial dysfunction, oxidative stress, and lipid handling failures set the stage for drusen and cell death, and what conventional care does well. Dr. Gandapodi explains the evidence behind anti-VEGF therapy and the AREDS trials, and where meaningful gaps remain.

He also introduces Netra Restoration Therapy, an integrative, adjunct approach aimed at supporting mitochondrial function, oxidative balance, and ocular blood flow. Throughout, the conversation stays honest about what is established, what is emerging, and what remains hypothesis.

Glaucoma is often described as a pressure disease, but at its core it's a disease of dying nerve cells. In this episode, Dr. Saikumar Gandapodi joins us to unpack what neuroprotection really means in glaucoma, why lowering eye pressure remains the foundation of care, and where the gaps in that approach open the door for adjunct strategies.

We explore the biology of retinal ganglion cell loss, the roles of ocular blood flow, mitochondrial function, oxidative stress, and neurotrophin decline, and what the human evidence actually supports versus what remains hypothesis. Dr. Gandapodi also explains how his integrative framework, Netra Restoration Therapy, is intended to complement conventional treatment rather than replace it.

This is a candid, evidence-informed conversation for anyone who wants to understand where glaucoma care is heading and how to think clearly about promise versus proof.